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Objectives
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Self-report antiretroviral therapy (ART) adherence has been consistently associated with
clinical outcomes. This study aims to compare the accuracy of self-report ART adherence
measures with varying recall timeframes or item contents to predict virological response.

Editor: Matt A. Price, International AIDS Vaccine
Initiative, UNITED STATES

Data from a cross-sectional study among 2146 participants on ART in Guangxi, China were
used. Detectable viral load was defined as viral load > 50 copies/ml. Adherence was measured using the number of days on which all doses were taken in the past month (i.e., the
“one-month days taken” measure), the number of days on which any dose was missed in
the past month (i.e., the “one-month days missed” measure), missed doses over the past 3
days, and missed days over the past weekend. Each adherence measure was dichotomized
at an empirically determined cut-off to determine poor vs. good adherence. Accuracy of
using each dichotomized adherence measure to predict detectable viral load was assessed
by sensitivity, specificity, and the area under the receiver-operating characteristic (AUROC)
curve. Logistic regressions were used to calculate the association between poor adherence
and detectable viral load.
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Methods

Results
All four measures had sensitivity below 10.0%, specificity above 90.0%, and AUROC slightly
above 0.50. In univariate logistic regression, detectable viral load was statistically significantly associated with poor adherence determined by the one-month days taken measure
(OR = 1.98, 95% CI 1.15–3.42), the 3-day measure (OR = 2.18, 95% CI 1.10–4.34), and the
weekend measure (OR = 2.86, 95% CI 1. 54–5.34). After adjusting for covariates, statistically significant association persisted only for the weekend measure (OR = 2.57, 95% CI
1.33–4.99).
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Conclusions
Adherence measures asking about days on which all doses were taken might work better
than items asking about days on which respondents missed their doses, and weekend measures should be included to comprehensively capture adherence behaviors. Further studies
looking at intermediate timeframes are also needed to capture patients’ dose-missing patterns that may better predict detectable viral load.

Introduction
According to the 2015 China AIDS Response Progress Report, there were 501,000 reported
people living with HIV (PLHIV) in China by the end of 2014 [1]. Access to antiretroviral therapy (ART) is rapidly expanding in these years, with the number of PLHIV who were currently
receiving ART increasing from 126,448 in 2011 to 295,358 in 2014 nationwide [1]. In 2014, the
Joint United Nations Programme on HIV and AIDS (UNAIDS) launched its ambitious 90-9090 target for 2020, with the third target requiring 90% of patients on ART reaching viral suppression [2]. Although some countries are already remarkably close to achieving the third 90,
China has been identified as one of the countries furthest from achieving this target in a 2016
meta-analysis of national HIV treatment programmes, with only 36% of PLHIV on ART
achieving viral suppression (defined as VIRAL LOAD < 1000 copies/mL) [3]. Better virological responses were found by Huang et al. who followed PLHIV in Shenzhen, China over 10
years, where the rate of virological failure (defined as VIRAL LOAD  1000 copies/mL) was
6.7% at month 6 but increased to 31.5% at month 96 [4].
Poor ART adherence has been identified as one of the most important causes of virological
failure, and once it occurs, improving adherence at that point may be too late with the possible
emergence of drug-resistant virus [5]. Therefore, detecting and addressing poor ART adherence is a crucial step in the continuum of HIV care. Some clinical studies employed objective
measures of ART adherence such as biomarkers and electronic monitoring devices [6]. The
application of these measures, however, was limited in both clinical and research settings
despite their high accuracy because of high cost and logistical complexities. Therefore, selfreport still remained the most widely used adherence measure, which was found to be highly
correlated with objective adherence measures [7–9]. However, there is a lack of consensus
among both researchers and practitioners on the best self-report measure which often comes
with different recall timeframes and item contents. Finding a relatively accurate and easy-toimplement self-report adherence measure, therefore, is important in monitoring and enhancing HIV treatment success as it provides an opportunity to intervene before clinical outcomes
deteriorate.
One primary challenge related to self-report adherence measures is that these measures are
prone to various biases such as social desirability and recall-error which could threat the internal validity [7]. Because of such challenge, the validity of self-report ART adherence measures
has also been widely assessed using various criteria including virological response [8]. Most of
the existing studies have assessed the correlation between ART adherence and virological
response using single self-report measure with limited options of recall timeframes (e.g., recent
3-day, weekend, or one month), item contents (e.g., missed doses or missed days), and
response tasks (e.g., frequencies of events, or numbers of events) [8]. Of limited studies comparing self-report adherence measures with different timeframes, many had small sample
sizes, or assessed only convergent validity using device-based adherence as the criterion [10–
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13]. Studies comparing the predictive validity of self-report ART adherence measures with different recall timeframes and item contents using virological response as the criterion were
even fewer.
The primary objective of the current study is to identify the optimal recall timeframe and
item content of self-report ART adherence measures that best predict virological response.
Utilizing cross-sectional data from a large representative sample of PLHIV in China, we compared the performance of four self-report ART adherence measures with different recall duration and item content in predicting detectable viral load by calculating sensitivity, specificity,
and the area under the receiver-operating characteristic curve (AUROC). In addition, we
assessed the association between the four self-report ART adherence measures and detectable
viral load while controlling for potential sociodemographic, behavioral, and clinical covariates.

Materials and methods
Study design
Data in the current study were derived from a cross-sectional survey conducted from October
2012 to August 2013 in the Guangxi Autonomous Region (“Guangxi”) of China. Details of the
study design have been published elsewhere [14]. Briefly, we selected 12 sites with the largest
cumulative number of reported HIV/AIDS cases from 17 cities and 75 counties in Guangxi.
The inclusion criteria were as follows: confirmed diagnosis of HIV infection; age 18 years or
older; having the mental competence to provide informed consent and complete the survey.
Approximately 10% of the patients at each site were randomly sampled, and a total of 3002
patients (about 90% of those contacted) agreed to participate. The survey was conducted in
offices of local Center for Disease Control and Prevention (CDC) or HIV clinics where the
participants received medical care. A total of 2987 participants completed the survey. Each participant received a small gift equivalent to five U.S dollars as a token of appreciation at completion of the survey.

Ethical statement
The study protocol was reviewed and approved by the Institutional Review Boards at Wayne
State University in the U.S and Guangxi CDC in China. All participants provided written
informed consent prior to participation in the survey.

Measures
Viral load. Participants’ most recent viral load data were retrieved from their medical records. Detectable viral load was defined as viral load > 50 copies/ml, a threshold used to determine virological failure in the 2011 China Guideline of Diagnosis and Treatment for AIDS
[15].
ART adherence measures. Four self-report measures were used to assess patients’ ART
adherence over the last month, the past 3-days, and the past weekend prior to the study visit.
For the one-month days taken measure, participants were asked to report the number of days
they took all doses of their HIV medication as prescribed. Percent adherence was calculated
dividing the reported number of days by 30 days. For the one-month days missed measure,
participants were asked to report the number of days on which they did not take any dose of
their HIV medication. Percent adherence was calculated by first subtracting the reported number of days missed from 30 days and then dividing the result by 30 days. For the 3-day adherence measure, participants were asked to report the number of doses taken and the number of
expected doses during the past three days. Percent adherence was calculated dividing doses
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taken by doses expected. For the weekend adherence measure, participants were asked
whether they took their HIV medication on both, either, or neither days over the past
weekend.
Covariates. Alcohol use was measured by the Alcohol Use Disorders Identification Test
Consumption (AUDIT-C) questionnaire, and depression was measured by the 10-item Center
for Epidemiologic Studies–Depression (CESD-10) scale [16,17]. Information on substance use
and sociodemographic characteristics such as age, gender, ethnicity, education, household
monthly income was also collected during the survey. Time on ART and most recent CD4
count were retrieved from medical record.

Analysis
All analysis was conducted using Stata 13.0 (College Station, Texas). As viral load data were
only available for some participants, we examined differences in sociodemographic, behavioral, and clinical characteristics between those with and without viral load data. T-tests (for
continuous variables) and chi-square tests (for categorical or binary variables) were used in the
bivariate analysis.
Further analysis was conducted among participants on ART for at least 6 months, had viral
load data, and responded to at least one self-reported ART adherence questions (n = 1535).
Detectable viral load (i.e., viral load > 50 copies/ml) was coded as 1 and undetectable viral
load (i.e., viral load  50 copies/ml) was coded as 0. To empirically determine the cut-offs of
percent adherence to define poor (i.e., percent adherence below the cut-off) vs. good adherence (i.e., percent adherence no less than the cut-off), we employed pre-defined cut-offs of
100%, 95%, 90%, 85%, and 80% for the three continuous adherence measures to see which cutoff would produce a dichotomized variable that statistically significantly correlated with
detectable viral load. Cut-offs were calculated using the receiver operator curve (ROC) analysis
in cases where none of the pre-defined cut-offs worked. For the ordinal weekend adherence
measure, Fisher’s exact test (and post-hoc pair-wise comparisons with Bonferroni correction)
was used to determine if there were significant differences in detectable viral load across
groups. Kappa coefficients were calculated to examine the potential overlap among the four
adherence measures.
Accuracy of using ART adherence measures (i.e, “the test”) to predict detectable viral load
(i.e, “the disease”) was evaluated by calculating sensitivity, specificity, and area under the
receiver operator curve (AUROC). Sensitivity was defined as the proportion of participants
who self-reported as poorly adherent among those who had detectable viral load. Specificity
was defined as the proportion of participants who self-reported as adherent among those who
had undetectable viral load. Covariate-adjusted AUROC was also calculated.
Chi-square tests were used to examine the relationship between adherence and detectable
viral load. Univariate logistic regression was used to calculate the odd ratio (OR) of using poor
adherence to predict detectable viral load. Adjusted OR for poor adherence determined by
each ART adherence measure was calculated with four separate multiple logistic regression
models controlling for age, gender, substance use, alcohol use, depression, time on ART, and
CD4 count.

Results
The flowchart of participants included in this study was shown in Fig 1. Sociodemographic,
behavioral, and clinical characteristics of participants with (n = 1535) and without (n = 519)
viral load data were shown in Table 1. The two groups were similar in terms of sociodemographic, behavioral, and clinical characteristics except gender, ethnicity, employment status,
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Fig 1. CONSORT flowchart of participants included in the study.
https://doi.org/10.1371/journal.pone.0203032.g001

time on ART, CD4 count, and depression. Participants without viral load data were more
likely to be males and of Han ethnicity but less likely to be employed. They also had shorter
duration on ART, lower CD4 count, and higher depression scores.
Among the 1535 participants who had viral load data, the mean age was 42.5 years old
(SD = 12.3 years), and most were males (915/1535, 59.6%). Most (983/1533, 64.1%) were of
Han ethnicity (the largest ethnic group in China), less than half (655/1533, 42.7%) completed
elementary education only, most (1142/1530, 74.6%) were employed, and about half (779/
1526, 51.0%) had a monthly household income less than 1000 RMB (Chinese currency, which
equaled approximately 160 US dollars at the time of the survey). The majority (1062/1502,
70.7%) had a marital or live-in partner, and most (1380/1524, 90.5%) had health insurance.
The average time on ART was 39.2 months (SD = 23.5), and more than half (885/1535, 57.6%)
had CD4 counts less than or equal to 350 cells/mm3. The average AUDIT-C score was 1.8
(SD = 2.5), 15.9% (244/1531) participants had used drugs, and the average CESD-10 score was
8.6 (SD = 5.9).

Table 1. Demographical and clinical characteristics among participants receiving ART in Guangxi, China.
Variables

Participants with viral load data
N = 1535a

Age (Mean±SD)

42.5±12.3

42.2±13.0

0.604

Male: n(%)

915(59.6)

340(65.5)

0.017

Han ethnicity: n(%)

983(64.1)

427(82.3)

<0.001

Elementary school

655(42.7)

240(46.6)

0.306

Middle school

658(42.9)

205(39.8)

Participants without viral load data
N = 519a

P value

Education completed: n(%)

220(14.4)

70(13.6)

Employed: n(%)

High school or higher

1142(74.6)

362(70.2)

0.046

Monthly income < 1000 RMB: n(%)

779(51.0)

279(54.4)

0.191
0.062

Marital status: n(%)
Never married

123(8.2)

44(8.7)

Having a marital/live-in partner

1062(70.7)

377(74.8)

Divorced/separated

122(8.1)

40(7.9)

Widowed

195(13.0)

43(8.5)

1380(90.6)

465(90.5)

0.955

Mean±SD

39.2±23.5

23.6±21.2

<0.001

Median (range)

34 (6–157)

15 (6–123)

<0.001

<350

885(57.6)

315(67.0)

0.001

350–499

365(23.8)

92(19.6)

With health insurance: n(%)
Time on ART by month

CD4 cell count (cells/μl): n(%)

285(18.6)

63(13.4)

Alcohol use (Mean±SD)

500

1.8±2.5

1.9±2.6

0.447

Drug use: n(%)

244(15.9)

93(18.0)

0.269

Depression (Mean±SD)

8.6±5.9

9.6±6.0

<0.001

a

Not all the proportion was based on the entire sample due to missing data for some variables.

https://doi.org/10.1371/journal.pone.0203032.t001
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Cut-offs for determining poor vs. good adherence
The one-month days missed measure was not significantly correlated with detectable viral
load across all five pre-defined cut-offs ranging from 100% to 80%. Therefore, we decided to
use the cut-off at 88.3% determined by the ROC curve analysis. Poor adherence was determined as having a percent adherence lower than 88.3%.
The one-month days taken measure and detectable viral load were not significantly correlated until the pre-defined cut-off dropped to 90% (Chi-square = 7.46, p = 0.006). Therefore,
poor adherence was determined as having a percent adherence lower than 90.0%.
The 3-day measure was significantly correlated with detectable viral load at the cut-off of
100% (Chi-square = 5.08, p = 0.024). Therefore, poor adherence was determined as having a
percent adherence lower than 100%.
For the weekend measure, significant difference in detectable viral load was only found
between those who reported no missing during the last weekend, and those who reported
missing two days (Chi-square = 11.20, p = 0.001). Therefore, poor adherence was determined
as missing any day during the weekend.
Kappa coefficient across the four measures were shown in Table 2, where low to medium
concordance (0.14–0.34) was detected.

Sensitivity, specificity, and AUROC
Sensitivity, specificity, and AUROC of using adherence to predict detectable viral load were
summarized in Table 3. All four measures had a high specificity, suggesting that reaching viral
suppression was mostly related to good ART adherence. The sensitivity was below 10% for all
four measures, suggesting that poor adherence was only a partial explanation for detectable
viral load. The AUROC (Fig 2) for predicting detectable viral load ranged from 0.51 to 0.53,
and were not significantly different across the four measures. After adjusting for covariates,
the AUROC increased to 0.68 for all four measures (Fig 3).

Logistic regression
The results of univariate and multivariate logistic regression models were shown in Table 3. In
univariate regression, detectable viral load was statistically significantly associated with poor
adherence determined by the one-month days taken measure (OR = 1.98, 95% CI 1.15–3.42), the
3-day measure (OR = 2.18, 95% CI 1.10–4.34), and the weekend measure (OR = 2.86, 95% CI 1.
54–5.34). After adjusting for covariates, statistically significant association persisted only for poor
adherence determined by the weekend measure (OR = 2.57, 95% CI 1.33–4.99). Marginally significant associations were found for poor adherence determined by the one-month days taken measure (OR = 1.75, 95% CI 0.98–3.13) and the 3-day measure (OR = 2.04, 95% CI 0.99–4.18).

Discussion
To the best of our knowledge, this study is one of the first efforts to empirically assess the accuracy of using self-report ART adherence to predict detectable viral load among PLHIV in
Table 2. Kappa coefficient across the four adherence measures.
Adherence measure
One-month days missed

One-month days missed

One-month days taken

3-day

Weekend

1

0.34

0.14

0.25

1

0.29

0.32

1

0.26

One-month days taken
3-day
Weekend

1

https://doi.org/10.1371/journal.pone.0203032.t002
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Table 3. Predictive validity of adherence measures: sensitivity, specificity, AUROC, and odds ratio (OR).
Adherence measures

Detectable viral load
Yes

Sensitivity

Specificity

AUROC

Adjusted AUROCa

OR

AORa

No

P value
0.100

9.2(5.9, 13.4)

93.7(92.2, 95.0)

0.51(0.49, 0.53)

0.68(0.64, 0.71)

1.50(0.92, 2.43)

1.41(0.84, 2.37)

0.012

7.6(4.7, 11.7)

96.0(94.8, 97.0)

0.52(0.50, 0.54)

0.68(0.64, 0.71)

1.98(1.15, 3.42)

1.75(0.98, 3.13)

0.023

4.9(2.6, 8.4)

97.7(96.7, 98.5)

0.51(0.50, 0.53)

0.68(0.64, 0.71)

2.18(1.10, 4.34)

2.04 (0.99, 4.18)

0.001

6.5(3.8, 10.3)

97.6(96.6, 98.4)

0.52(0.50, 0.54)

0.68(0.64, 0.72)

2.86(1.54, 5.34)

2.57(1.33, 4.99)

One-month days missed
Poor adherence

23(22.2)

81(77.9)

Good adherence

228(15.9)

1203(84.1)

Poor adherence

19(27.1)

51(72.9)

Good adherence

230(15.8)

1225(84.2)

Poor adherence

12(29.3)

29(70.7)

Good adherence

234(15.9)

1235(84.1)

Poor adherence

16(34.8)

30(65.2)

Good adherence

231(15.7)

1240(84.3)

One-month days taken

3-day

Weekend

a

Adjusting for age, gender, time on ART, CD4, substance use, alcohol use, and depression.

https://doi.org/10.1371/journal.pone.0203032.t003

China using a large representative sample. All four adherence measures had sensitivity below
10.0%, specificity above 90.0%, and AUROC slightly above 0.5. In univariate analysis, selfreported poor adherence determined either by the one-month days taken measure, the 3-day
measure, or the weekend measure, increased the odds of having detectable viral load. No statistically significant association was found between the one-month days missed measure and
detectable viral load. However, after adjusting for covariates, statistically significant association
persisted only for the weekend measure.

Fig 2. Prediction of detectable viral load by each self-reported ART adherence measure. Receiver operating
characteristic (ROC) curves based on the univariate logistic regression model are shown.
https://doi.org/10.1371/journal.pone.0203032.g002
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Fig 3. Prediction of detectable viral load by each self-reported ART adherence measure. Receiver operating
characteristic (ROC) curves based on the multiple logistic regression model are shown.
https://doi.org/10.1371/journal.pone.0203032.g003

Sensitivity, specificity, and AUROC
Low sensitivity, high specificity, and low AUROC were detected in this study, which was consistent with previous studies assessing the validity of self-reported ART adherence measures to
predict virological failure [18,19]. The high specificity for all four adherence measures suggested that good adherence is necessary to reach viral suppression, while the low sensitivity
suggested that poor adherence was not the only factor that can be accountable for detectable
viral load. Factors other than adherence may also influence virological response, including
viral susceptibility, drug absorption and metabolism, potency of the regimen, as well as host
immune status [20]. In addition, the improvement in the AUCs after adjusting for covariates
suggested that the inclusion of potential confounders could improve the predictive validity of
ART adherence measures.

Differences in item content for the two one-month measures
For the one-month days taken measure, participants were asked about the number of days on
which they took all the medication, while for the one-month days missed measure, participants
were asked about the number of days on which they did not take any of their medication. Theoretically, responses to the two one-month measures should be highly correlated. However,
only the one-month days taken measure was associated with detectable viral load in univariate
logistic regression. One possible explanation was that, compared with the one-month days
missed measure where participants were counted as “adherent” as long as they took their medication (not necessarily all doses as prescribed), the former employed a stricter criterion which
better distinguished between good and poor adherence. Another explanation was that the
behavior we asked participants to report differed between the two measures. As argued by Wilson et al., asking patients who are unintentionally nonadherent about missed doses may
increase the risk that they will report an intention instead of action [21]. In our case, it is
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possible that participants’ responses to the “missed” question were biased towards underreporting their poor adherence behaviors.

Optimal recall timeframe
Our results indicated that the one-month days taken measure might have similar accuracy
compared with the 3-day measure as both were statistically significantly associated with detectable viral load in univariate logistic regression. After adjusting for covariates, marginally significant association was found for both measures. Although these two measures used different
item contents (days versus doses), the one-month measure took dosing into consideration by
applying a stricter criterion when defining adherence.
Longer timeframes may be less accurate because of its susceptibility to recall bias. Wilson
et al. stated that patients cannot recall and enumerate specific pill-taking events and instead
they answer adherence questions by estimating, which is often inaccurate [21]. However, Lu
et al. argued that longer timeframes may capture the variation in adherence behaviors therefore is more clinically relevant [13]. Also, as participants in our study were recruited and
assessed in the clinical settings where they received routine medical care, shorter timeframes
could be more impacted by “white coat” effect where patients do better in adherence for the
few days before the appointment [22]. Compared with the 3-day measure, the one-month
measure was also less biased as a recall error for a single missed dose would have more weight
with the short timeframe compared with the longer timeframe.
Ceiling effect is often a major concern for measuring socially desirable behaviors such as
adherence. This type of measurement error results in a measure concentrating at the top of the
scale with little variation to explain analytically [23]. In our study, the mean percent adherence
did not vary much between the 3-day measure and the one-month days taken measure, but the
one-month measure captured greater variation in adherence behaviors and identified more
patients who self-reported as poorly adherent. Therefore, one-month recall timeframe was less
susceptible to ceiling effect.

The weekend measure
After adjusting for covariates, only the weekend measure was statistically significantly associated with detectable viral load. Therefore, we may infer that weekend measure has higher accuracy in predicting detectable viral load compared with the other three measures which may
pick up both weekday and weekend adherence behaviors.
Disruption of daily routine has been identified as a major barrier to medication adherence,
which often happens during the weekends when people take their “drug holidays” [24]. Considering the fluctuation of weekly adherence patterns as well as its health implications, Chesney et al. recommended asking about adherence during the last four days rather than only the
last two days in the Adult AIDS Clinical Trials Group (AACTG) adherence instruments as this
would increase the likelihood of including a weekend day [25]. Our study further supported
the inclusion of weekend adherence behaviors when measuring ART adherence, which has
critical implications for prevention and adherence interventions.

Limitations
The study has several limitations. First, data were not available on viral load before ART initiation. Although we considered several important confounders of the relationship between
adherence and detectable viral load (e.g., most recent CD4 count, substance use and depression), we did not have access to information on participants’ CD4 count or viral load prior to
ART initiation, which are critical predictors of virological response. Second, information
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regarding laboratory procedures used to determine viral load was not available. Third, limited
by space in the survey, we were not able to use the “ideal comparison” (i.e., identical format
and different timeframes) to identify the optimal recall timeframe. It is possible that item content (e.g., doses versus days), not the recall timeframe, was responsible for the difference in
accuracy. Finally, dosing frequency might modify the relationship between medication adherence and virological response, yet participants’ ART regimen information was not available.

Conclusions
While it is widely agreed on the importance to promote adherence before virological failure
and ART resistance mutations occur, questions remain regarding identifying accurate and feasible measure of ART adherence in clinical settings. This study compared the predictive validity of four self-report ART adherence measures calculated from either missed doses or missed
days of varying timeframes with detectable viral load, yielding several key findings. First, we
found that items asking about days on which all doses were taken might work better than
items asking about days on which respondents missed their doses, especially for those who
were unintentionally nonadherent. Second, in terms of recall timeframes, one-month recall
can be of similar accuracy compared with 3-day recall, suggesting that one month can be a
valid recall timeframe despite concerns for recall bias. Third, weekend adherence was most
consistently associated with detectable viral load. As argued by Stirratt et al., determining the
optimal recall timeframe requires balancing shorter intervals with longer intervals [7]. Further
research comparing one month and weekend recall with intermediate timeframes (e.g., 7-day,
14-day) is needed to shed light on the weekly pattern of adherence behaviors and help optimize
the selection of ART adherence intervention strategies.
In summary, our study suggests that the association between self-report measure of ART
adherence and detectable viral load differs by recall timeframe and item content. Besides predictive validity, construct validity and convergent validity are also important, and we need further studies using cognitive interviewing and objective measures such as pill counts or
Medication Event Monitoring System (MEMS) to best assess the overall validity of self-report
measures.
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